CGT Development Is Booming, But Manufacturing Workforce Must Keep Up

Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.

CGT Development
• Source: Shutterstock

Research into workforce demands in cell and gene therapy, conducted by Citeline in collaboration with the Alliance for Regenerative Medicine (ARM) and performed with industry and academic subject matter experts, was prompted by an executive order issued by the Biden administration in September 2022 to launch the National Biotechnology and Biomanufacturing Initiative. The order aims to coordinate the US government’s approach to advance biotechnology and biomanufacturing toward innovative solutions in multiple sectors. ARM shared the results of the qualitative and quantitative research publicly in their workforce gap analysis report, published in March 2023.

The cell and gene therapy sector has expanded tremendously, with the number of drugs in development growing nearly six-fold from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.